21 white LO/OVRAL tablets, each containing 0.3 mg of norgestrel ( dl -13-beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon- 4-en-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol (19-nor-17(alpha)-pregna-1,3,5(10)-trien-20- yne-3,17-diol), and 7 pink inert tablets. The inactive ingredients present are cellulose, D&C Red 30, lactose, magnesium stearate, and polacrilin potassium.
See LO/OVRAL®.
See LO/OVRAL.
See LO/OVRAL.
See LO/OVRAL.
See LO/OVRAL.
Drug Interactions: See LO/OVRAL.
Carcinogenesis: See LO/OVRAL.
Pregnancy: See LO/OVRAL.
Nursing Mothers: See LO/OVRAL.
Information for the Patient: See LO/OVRAL.
See LO/OVRAL.
See LO/OVRAL.
See LO/OVRAL.
To achieve maximum contraceptive effectiveness, LO/OVRAL-28 must be taken exactly as directed and at intervals not exceeding 24 hours.
The dosage of LO/OVRAL-28 is one white tablet daily for 21 consecutive days, followed by one pink inert tablet daily for 7 consecutive days, according to prescribed schedule. It is recommended that tablets be taken at the same time each day, preferably after the evening meal or at bedtime.
During the first cycle of medication, the patient is instructed to begin taking LO/OVRAL-28 on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, the first tablet (white) is taken that day. One white tablet should be taken daily for 21 consecutive days followed by one pink inert tablet daily for 7 consecutive days. Withdrawal bleeding should usually occur within three days following discontinuation of white tablets. During the first cycle, contraceptive reliance should not be placed on LO/OVRAL-28 until a white tablet has been taken daily for 7 consecutive days. The possibility of ovulation and conception prior to initiation of medication should be considered.
The patient begins her next and all subsequent 28-day courses of tablets on the same day of the week (Sunday) on which she began her first course, following the same schedule: 21 days on white tablets--7 days on pink inert tablets. If in any cycle the patient starts tablets later than the proper day, she should protect herself by using another method of birth control until she has taken a white tablet daily for 7 consecutive days.
If spotting or breakthrough bleeding occurs, the patient is instructed to continue on the same regimen. This type of bleeding is usually transient and without significance; however, if the bleeding is persistent or prolonged, the patient is advised to consult her physician. Although the occurrence of pregnancy is highly unlikely if LO/OVRAL-28 is taken according to directions, if withdrawal bleeding does not occur, the possibility of pregnancy must be considered. If the patient has not adhered to the prescribed schedule (missed one or more tablets or started taking them on a day later than she should have), the probability of pregnancy should be considered at the time of the first missed period and appropriate diagnostic measures taken before the medication is resumed. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing the contraceptive regimen.
For additional patient instructions regarding missed pills, see the "WHAT TO DO IF YOU MISS PILLS" section in the DETAILED PATIENT LABELING for LO/OVRAL.
Any time the patient misses two or more white tablets, she should also use another method of contraception until she has taken a white tablet daily for seven consecutive days. If the patient misses one or more pink tablets, she is still protected against pregnancy provided she begins taking white tablets again on the proper day.
If breakthrough bleeding occurs following missed white tablets, it will usually be transient and of no consequence. While there is little likelihood of ovulation occurring if only one or two white tablets are missed, the possibility of ovulation increases with each successive day that scheduled white tablets are missed.
In the nonlactating mother, LO/OVRAL-28 may be initiated postpartum, for contraception. When the tablets are administered in the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see " Contraindications ," " ," and " Precautions " concerning thromboembolic disease). It is to be noted that early resumption of ovulation may occur if Parlodel® (bromocriptine mesylate) has been used for the prevention of lactation.
LO/OVRAL®-28 Tablets (0.3 mg norgestrel and 0.03 mg ethinyl estradiol) are available in packages of 6 PILPAK® dispensers, each containing 28 tablets as follows:
21 active tablets, NDC 0008-0078, white, round tablet marked "WYETH" and "78".
7 inert tablets, NDC 0008-0486, pink, round tablet marked "WYETH" and "486".
ALSO AVAILABLE:
LO/OVRAL®-28 Tablets (0.3 mg norgestrel and 0.03 mg ethinyl estradiol) are available in packages of 12 PILPAK® dispensers for clinic use only, each containing 28 tablets as follows:
21 active tablets, NDC 0008-0078, white, round tablet marked "WYETH" and "78".
7 inert tablets, NDC 0008-0486, pink, round tablet marked "WYETH" and "486".
Store at room temperature, approx. 25°C (77°F).
![]() |
![]() |
Brief Summary Patient Package Insert: See LO/OVRAL.
DETAILED PATIENT LABELING: See LO/OVRAL.
For Lo/Ovral-28 PILPAK® Dispenser, See LO/OVRAL.
For Lo/Ovral-28 Clinic Pilpak®, See below.
This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis.
BEFORE YOU START TAKING YOUR PILLS:
BEFORE YOU START TAKING YOUR PILLS
WHEN TO START THE FIRST PACK OF PILLS:
For the 21-day pill pack you have two choices of which day to start taking your first pack of pills. (See DAY 1 START or SUNDAY START directions below.) Decide with your doctor or clinic which is the best day for you. The 28-day pill pack accommodates a SUNDAY START only. For either pill pack pick a time of day which will be easy to remember.
These instructions are for the 21-day pill pack only. The 28-day pill pack does not accommodate a DAY 1 START dosage regimen.
These instructions are for either the 21-day or the 28-day pill pack.
If you MISS 1 white or light-orange "active" pill:
If you MISS 2 white or light-orange "active" pills in a row in WEEK 1 OR WEEK 2 of your pack:
If you MISS 2 white or light-orange "active" pills in a row in THE 3rd WEEK:
The Day 1 Starter instructions are for the 21-day pill pack only. The 28-day pill pack does not accommodate a DAY 1 START dosage regimen. The Sunday Starter instructions are for either the 21-day or 28-day pill pack.
If you MISS 3 OR MORE white or light-orange "active" pills in a row (during the first 3 weeks):
The Day 1 Starter instructions are for the 21-day pill pack only. The 28-day pill pack does not accommodate a DAY 1 START dosage regimen. The Sunday Starter instructions are for either the 21-day or 28-day pill pack.
If your forget any of the 7 pink "reminder" pills in Week 4:
THROW AWAY the pills you missed.
Keep taking 1 pill each day until the pack is empty.
You do not need a back-up method if you start your next pack on time.
Use a BACK-UP METHOD anytime you have sex.
KEEP TAKING ONE PILL EACH DAY until you can reach your doctor or clinic.
OVRETTE®
Ovrette is administered on a continuous daily dosage schedule, one tablet each day, every day of the year. Take the first tablet on the first day of your menstrual period. Tablets should be taken at the same time every day without interruption, whether bleeding occurs or not. If bleeding is prolonged (more than 8 days) or unusually heavy, you should contact your doctor.
Forgotten pills
The risk of pregnancy increases with each tablet missed. Therefore, it is very important that you take one tablet daily as directed. If you miss one tablet, take it as soon as you remember and also take your next tablet at the regular time. If you miss two tablets, take one of the missed tablets as soon as you remember, as well as your regular tablet for that day at the proper time. Furthermore, you should use another method of birth control in addition to taking Ovrette until you have taken fourteen days (2 weeks) of medication.
If more than two tablets have been missed, Ovrette should be discontinued immediately and another method of birth control used until the start of your next menstrual period. Then you may resume taking Ovrette.
The incidence of pill failure resulting in pregnancy is approximately less than 1.0% if taken every day as directed, but more typical failure rates are less than 3.0%. If failure does occur, the risk to the fetus is minimal.
RISKS TO THE FETUS
If you do become pregnant while using oral contraceptives, the risk to the fetus is small, on the order of no more than one per thousand. You should, however, discuss the risks to the developing child with your doctor.
Pregnancy after stopping the pill
There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had irregular menstrual cycles before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy.
There does not appear to be any increase in birth defects in newborn babies when pregnancy occurs soon after stopping the pill.
Overdosage
Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause nausea and withdrawal bleeding in females. In case of overdosage, contact your health-care provider or pharmacist.
Other information
Your health-care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health-care provider believes that it is appropriate to postpone it. You should be reexamined at least once a year. Be sure to inform your health-care provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your health-care provider, because this is a time to determine if there are early signs of side effects of oral-contraceptive use.
Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth-control pills.
HEALTH BENEFITS FROM ORAL CONTRACEPTIVES: See LO/OVRAL.
Manufactured by:
Wyeth Laboratories
A Wyeth-Ayerst Company
Philadelphia, PA 19101
CI 4259-3 Revised August 14, 1996